$1.58
13.19% today
Nasdaq, Apr 04, 07:45 pm CET
ISIN
US09075P1057
Symbol
BTAI
Sector
Industry

BioXcel Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation

BioXcel Therapeutics, Inc. Classifications & Recommendation:

Buy
75%
Sell
25%

BioXcel Therapeutics, Inc. Price Target

Target Price $48.50
Price $1.82
Potential
Number of Estimates 4
4 Analysts have issued a price target BioXcel Therapeutics, Inc. 2026 . The average BioXcel Therapeutics, Inc. target price is $48.50. This is higher than the current stock price. The highest price target is
$80.00 4,295.60%
register free of charge
, the lowest is .
A rating was issued by 4 analysts: 3 Analysts recommend BioXcel Therapeutics, Inc. to buy, 0 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the BioXcel Therapeutics, Inc. stock has an average upside potential 2026 of . Most analysts recommend the BioXcel Therapeutics, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 2.27 4.85
64.49% 113.62%
EBITDA Margin -2,782.82% -1,645.76%
76.87% 40.86%
Net Margin -3,210.62% -1,357.18%
85.47% 57.73%

5 Analysts have issued a sales forecast BioXcel Therapeutics, Inc. 2025 . The average BioXcel Therapeutics, Inc. sales estimate is

$4.8m
Unlock
. This is
113.62% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$14.2m 524.02%
Unlock
, the lowest is
$1.5m 35.51%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $2.3m 64.49%
2025
$4.8m 113.62%
Unlock
2026
$11.9m 145.71%
Unlock
2027
$109m 818.18%
Unlock
2028
$196m 78.70%
Unlock
2029
$295m 50.90%
Unlock

3 Analysts have issued an BioXcel Therapeutics, Inc. EBITDA forecast 2025. The average BioXcel Therapeutics, Inc. EBITDA estimate is

$-79.8m
Unlock
. This is
26.33% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-65.7m 4.01%
Unlock
, the lowest is
$-106m 67.16%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-63.2m 61.95%
2025
$-79.8m 26.33%
Unlock
2026
$-78.1m 2.13%
Unlock
2027
$-15.6m 80.03%
Unlock
2028
$46.9m 400.64%
Unlock
2029
$125m 166.52%
Unlock

EBITDA Margin

2024 -2,782.82% 76.87%
2025
-1,645.76% 40.86%
Unlock
2026
-655.56% 60.17%
Unlock
2027
-14.26% 97.82%
Unlock
2028
23.99% 268.23%
Unlock
2029
42.37% 76.62%
Unlock

3 BioXcel Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average BioXcel Therapeutics, Inc. net profit estimate is

$-65.8m
Unlock
. This is
18.07% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-24.3m 69.75%
Unlock
, the lowest is
$-101m 25.75%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-72.9m 76.10%
2025
$-65.8m 9.70%
Unlock
2026
$-51.5m 21.71%
Unlock
2027
$-7.4m 85.56%
Unlock
2028
$-2.5m 66.67%
Unlock
2029
$18.4m 839.92%
Unlock

Net Margin

2024 -3,210.62% 85.47%
2025
-1,357.18% 57.73%
Unlock
2026
-432.37% 68.14%
Unlock
2027
-6.80% 98.43%
Unlock
2028
-1.27% 81.32%
Unlock
2029
6.22% 589.76%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -23.51 -21.23
76.10% 9.70%
P/E negative
EV/Sales 17.13

3 Analysts have issued a BioXcel Therapeutics, Inc. forecast for earnings per share. The average BioXcel Therapeutics, Inc. EPS is

$-21.23
Unlock
. This is
18.06% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-7.84 69.74%
Unlock
, the lowest is
$-32.58 25.74%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-23.51 76.10%
2025
$-21.23 9.70%
Unlock
2026
$-16.62 21.71%
Unlock
2027
$-2.40 85.56%
Unlock
2028
$-0.80 66.67%
Unlock
2029
$5.92 840.00%
Unlock

P/E ratio

Current -0.07 84.78%
2025
-0.09 28.57%
Unlock
2026
-0.11 22.22%
Unlock
2027
-0.76 590.91%
Unlock
2028
-2.28 200.00%
Unlock
2029
0.31 113.60%
Unlock

Based on analysts' sales estimates for 2025, the BioXcel Therapeutics, Inc. stock is valued at an EV/Sales of

17.13
Unlock
and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 36.60 61.45%
2025
17.13 53.19%
Unlock
2026
6.97 59.30%
Unlock
2027
0.76 89.11%
Unlock
2028
0.43 44.03%
Unlock
2029
0.28 33.74%
Unlock

P/S ratio

Current 4.40 93.60%
2025
2.06 53.19%
Unlock
2026
0.84 59.30%
Unlock
2027
0.09 89.11%
Unlock
2028
0.05 44.08%
Unlock
2029
0.03 33.73%
Unlock

Current BioXcel Therapeutics, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Rodman & Renshaw
Locked
Locked
Locked Mar 19 2025
HC Wainwright & Co.
Locked
Locked
Locked Jan 30 2025
B of A Securities
Locked
Locked
Locked Jan 07 2025
Canaccord Genuity
Locked
Locked
Locked Jan 06 2025
HC Wainwright & Co.
Locked
Locked
Locked Oct 21 2024
HC Wainwright & Co.
Locked
Locked
Locked Sep 06 2024
Canaccord Genuity
Locked
Locked
Locked Aug 30 2024
Analyst Rating Date
Locked
Rodman & Renshaw:
Locked
Locked
Mar 19 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jan 30 2025
Locked
B of A Securities:
Locked
Locked
Jan 07 2025
Locked
Canaccord Genuity:
Locked
Locked
Jan 06 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Oct 21 2024
Locked
HC Wainwright & Co.:
Locked
Locked
Sep 06 2024
Locked
Canaccord Genuity:
Locked
Locked
Aug 30 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today